Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carboxynaphthol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4A | O75164 | 1/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carboxynaphthol SCHEMBL23832851 | 0.85 | LDHA (0.67) | LDHAMEN1KMT2ACTDSP1CYP2D6 | |
| Carboxynaphthol SCHEMBL25244 | 0.81 | LDHA (1.00) | LDHAMEN1KMT2AMAPTKDM4E | |
| Carboxynaphthol SCHEMBL3770341 | 0.81 | LDHA (1.00) | LDHAMEN1KMT2AMAPTKDM4E | |
| Carboxynaphthol SCHEMBL2099330 | 0.81 | LDHA (1.00) | LDHAMEN1KMT2AMAPTKDM4E | |
| Phthalic Acid SCHEMBL5389196 | 0.79 | AKR1C3 (0.58) | MAPTCYP2D6KDM4EALDH1A1LMNA | |
| Carboxynaphthol SCHEMBL5429120 | 0.79 | LDHA (0.71) | LDHACYP2D6ALDH1A1HTTWDR5 | |
| Carboxynaphthol SCHEMBL10943009 | 0.79 | LDHA (0.96) | LDHAMEN1KMT2AMAPTKDM4E | |
| Carboxynaphthol SCHEMBL25369919 | 0.79 | LDHA (0.96) | LDHAMEN1KMT2AMAPTKDM4E | |
| Carboxynaphthol SCHEMBL25371193 | 0.79 | LDHA (0.96) | LDHAMEN1KMT2AMAPTKDM4E | |
| Carboxynaphthol SCHEMBL1458046 | 0.79 | LDHA (0.96) | LDHAMEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017992-B2 | Compounds for modulating mitochondrial function | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| US-11773219-B2 | Functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-09-14 | — | — | US | disclosed |
| US-11723981-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-08-15 | — | — | US | disclosed |
| US-20230022913-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-01-26 | — | — | US | disclosed |
| US-11382984-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-07-12 | — | — | US | disclosed |
| US-20220031856-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2022-02-03 | — | — | US | disclosed |
| US-20220017467-A1 | COMPOUNDS FOR MODULATING MITOCHONDRIAL FUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-01-20 | — | — | US | disclosed |
| US-11161814-B2 | Compounds for modulating mitochondrial function | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050222128-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| WO-2005092861-A1 | QUINOLINONE DERIVATIVES PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092841-A1 | COMPOUNDS HAVING BETA-AGONIST ACTIVITY | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092860-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005090288-A1 | PHENYLAMINOETHANOL DERIVATES AS BETA2 RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| US-20050215542-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | CD44, EPCAM, ALG1 | LDHA 889/4885MEN1 1803/4885KMT2A 3890/4885 |
| US-20230022913-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | LDHA 828/4885MEN1 2320/4885KMT2A 4039/4885 |
| US-11723981-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | TNF, TNFRSF1A, TNFSF11 | LDHA 828/4885MEN1 2320/4885KMT2A 4039/4885 |
| US-11773219-B2 | Functionalized polymers | PARG, PUF60, PCBP1 | LDHA 832/4885MEN1 4163/4885KMT2A 3491/4885 |
| US-20220017467-A1 | COMPOUNDS FOR MODULATING MITOCHONDRIAL FUNCTION | CYC1, UQCRC1, NLN | LDHA 2099/4885MEN1 3505/4885KMT2A 4516/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | LDHA 828/4885MEN1 2320/4885KMT2A 4039/4885 |
| US-11161814-B2 | Compounds for modulating mitochondrial function | CYC1, UQCRC1, NLN | LDHA 2099/4885MEN1 3505/4885KMT2A 4516/4885 |
| US-11382984-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | TNF, TNFRSF1A, TNFSF11 | LDHA 828/4885MEN1 2320/4885KMT2A 4039/4885 |
| US-20050215542-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, EPX | LDHA 969/4885MEN1 935/4885KMT2A 3614/4885 |
| US-20050222128-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, CYP11B2 | LDHA 822/4885MEN1 975/4885KMT2A 3620/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | LDHA 547/4885MEN1 1038/4885KMT2A 1595/4885 |
| US-20220031856-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | LDHA 828/4885MEN1 2320/4885KMT2A 4039/4885 |
| US-12017992-B2 | Compounds for modulating mitochondrial function | CYC1, UQCRC1, NLN | LDHA 2099/4885MEN1 3505/4885KMT2A 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.